ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

“This large dataset provided the opportunity to identify risk factors for [overall survival] post-relapse to inform trial design and highlight populations with dismal outcomes post-relapse,” the ...